Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab

Abstract Background The safety of pembrolizumab monotherapy in treatment‐naïve non‐small cell lung cancer (NSCLC) patients with high programed death‐ligand 1 (PD‐L1) expression and pre‐existing interstitial lung disease (ILD) has not yet been determined. Here, we aimed to evaluate the prognosis, eff...

Full description

Bibliographic Details
Main Authors: Ou Yamaguchi, Kyoichi Kaira, Shun Shinomiya, Atsuto Mouri, Kosuke Hashimoto, Ayako Shiono, Yu Miura, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, Hiroshi Kagamu
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Thoracic Cancer
Subjects:
Immune checkpoint inhibitor
interstitial lung disease
non‐small cell lung cancer
pembrolizumab
pneumonitis
Online Access:https://doi.org/10.1111/1759-7714.13725

Internet

https://doi.org/10.1111/1759-7714.13725

Similar Items